MaxCyte Affirms 2024 Revenue Guidance For Core Business Revenue To Be Flat To 5% Growth
Portfolio Pulse from Benzinga Newsdesk
MaxCyte has reaffirmed its revenue guidance for 2024, expecting its core business revenue to remain flat or grow up to 5%. The company also anticipates ending the year with at least $175 million in total cash, cash equivalents, and investments.
May 07, 2024 | 9:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MaxCyte reaffirms its 2024 revenue guidance with expectations of flat to 5% growth in core business revenue and projects to have over $175 million in cash and investments by the end of 2024.
Reaffirming revenue guidance, especially with a positive outlook on growth and financial stability, is generally received well by the market. This announcement could instill confidence in investors about MaxCyte's financial health and growth prospects, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100